Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Chaperone-Targeted Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CHORDC1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CHORDC1 Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for PPI screening. |
View CHORDC1 Products |
| Gene Delivery | CHORDC1 Lentivirus / Promise-ORF Full-length ORF for stable cell line generation and overexpression validation. |
View CHORDC1 Products |
| Benchmark Ab | Anti-CHORDC1 Recombinant Antibody High-affinity sequence-verified positive control for Western Blot, ELISA, and IHC. |
View CHORDC1 Products |
| Validator | CHORDC1 siRNA Set Target-specific knockdown verification to confirm phenotype and target engagement. |
View CHORDC1 Products |
| Related Target A | HSP90AA1 Primary chaperone partner; CHORDC1 acts as a co-chaperone to stabilize HSP90-client complexes. |
View HSP90AA1 Products |
| Related Target B | EGFR Key client protein stabilized by the HSP90-CHORDC1 complex; critical for resistance assays. |
View EGFR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) screening accuracy | High-purity CHORDC1 recombinant protein with intact CHORD domains verified by mass spectrometry. |
| Assay reproducibility in cellular models | Lentivirus premade particles ensuring stable integration and consistent expression levels. |
| Lack of Controls | Sequence-derived benchmark antibodies available for robust assay standardization. |
| False Positives | Validated siRNA pool included for target-specific gene silencing and specificity checks. |
Live CHORDC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CHORDC1 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum HSP90 inhibition to selective co-chaperone disruption. As first-generation systemic chaperone inhibitors face toxicity hurdles in the clinic, the next wave of R&D is targeting the specific CHORDC1-HSP90 interface to achieve tissue-selective client protein degradation, particularly in drug-resistant solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic & Biotech Consortia | Triple-Negative Breast Cancer, NSCLC | Selectivity Assay (Need Mutant vs WT Proteins and HSP90AA1 binding partners) |
| RNA Therapeutics (siRNA/ASO) | Preclinical Stage Developers | Refractory Solid Tumors, Metastatic Cancers | Knockdown Validation (Need high-titer Lentivirus and validated siRNA) |
| Combination Therapies | Oncology-focused Pharma | EGFR T790M/C797S Resistant Lung Cancer | Synergy Profiling (Need EGFR and downstream kinase pathway proteins) |